1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators

Details for Australian Patent Application No. 2003221706 (hide)

Owner Merck & Co., Inc.

Inventors Ali, Amjad; Thompson, Christopher F; Quraishi, Nazia; Balkovec, James M; Graham, Donald W

Agent Spruson & Ferguson

Pub. Number AU-B-2003221706

PCT Number PCT/US03/10867

PCT Pub. Number WO2003/086294

Priority 60/371,948 11.04.02 US

Filing date 8 April 2003

Wipo publication date 27 October 2003

Acceptance publication date 28 February 2008

International Classifications

A61K 31/416 (2006.01) - condensed with carbocyclic ring systems, e.g. indazole

A61K 31/4184 (2006.01)

A61K 31/427 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/428 (2006.01) - condensed with carbocyclic rings

A61K 31/4439 (2006.01)

A61K 31/4709 (2006.01) - Non-condensed quinolines containing further heterocyclic rings

A61K 31/4725 (2006.01)

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 1/16 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 3/14 (2006.01) Drugs for disorders of the metabolism

A61P 7/04 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

A61P 13/12 (2006.01) Drugs for disorders of the urinary system

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 17/14 (2006.01) Drugs for dermatological disorders

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 21/00 (2006.01) Drugs for disorders of the muscular or neuromuscular system

A61P 21/02 (2006.01) Drugs for disorders of the muscular or neuromuscular system

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

A61P 25/20 Drugs for disorders of the nervous system

Event Publications

7 August 2003 Complete Application Filed

  Priority application(s): 60/371,948 11.04.02 US

4 December 2003 Application Open to Public Inspection

  Published as AU-B-2003221706

28 February 2008 Application Accepted

  Published as AU-B-2003221706

26 June 2008 Standard Patent Sealed

21 January 2010 Amendment Made

  The nature of the amendment is: Amend patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

1 November 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003221707-TOPICAL USE OF HYDROXYEICOSATETRAENOIC ACID COMPOUNDS TO TREAT PSORIASIS

2003221705-SPIRAL WOUND FILTRATION MEMBRANE CARTRIDGE WITH CHEVRON SEAL